Generics would hit the market faster under Senate bill, saving more than $3B, says CBO

Generics would hit the market faster under Senate bill, saving more than $3B, says CBO -washingtonexaminer: Lower-price drugs would hit the market faster under a bipartisan bill awaiting a vote in the Senate, according to a score released Wednesday by the Congressional Budget Office and the Joint Committee on Taxation.

Drug Company ‘Shenanigans’ to Block Generics Come Under Federal Scrutiny

Drug Company ‘Shenanigans’ to Block Generics Come Under Federal Scrutiny-nytimes: Trump administration officials, seeking ways to lower drug costs, are targeting pharmaceutical companies that refuse to provide samples of their products to generic drug companies, making it impossible to create inexpensive generic copies of a brand-name medicine.

FDA charts path forward for biosimilars — but drug makers aren’t all on board

FDA charts path forward for biosimilars — but drug makers aren’t all on board-stat: In his recent public appearances, Food and Drug Administration Commissioner Scott Gottlieb has sounded a repeating note: drug prices are too high, and especially prices for complicated protein-based drugs called biologics.

Conservative Groups Warn Against Including Bill Targeting Generics in Cures Act

Conservative Groups Warn Against Including Bill Targeting Generics in Cures Act-morningconsult: Ten conservative organizations are warning lawmakers against adding a measure they say could cause unnecessary health risks to a medical innovation bill top lawmakers hope to advance before the year ends.